Cullinan Oncology is a US-based biopharmaceutical company working on targeted oncology and immuno-oncology therapies for cancer patients. They are developing a pipeline of products including CLN-081, CLN-049, CLN-619, CLN-617, CLN-978, Opal, and Jade. The company has collaboration agreements with Cullinan Pearl Corp. and Adimab, LLC to discover, manufacture, and commercialize their products.